ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • biosimilars and prescribing trends
  • biosimilars and psoriasis
  • Biosimilars and rheumatoid arthritis (RA)
  • Biosimilars and rituximab
  • biosimilars and safety
  • Biostatistics
  • bipolar disorder and mood disorder questionnaire
  • Bisphosphonates
  • bisphosphonates and denosumab
  • bisphosphonates and infliximab
  • bisphosphonates and osteoarthritis
  • bisphosphonates and osteoporosis
  • Bisphosphonates and pregnancy
  • BK virus
  • Blau syndrome
  • bleomycin
  • blindness
  • blood brain barrier
  • blood pressure
  • BLyS
  • BLyS and Lupus
  • BLyS and systemic lupus erythematosus (SLE)
  • BMD
  • bmi
  • BMI and obesity
  • bmi and physical activity
  • bmp and chondrocytes
  • body composition
  • Body image
  • body image and quality of life
  • Body image and systemic sclerosis
  • body mass
  • Body mass and disability
  • body mass and etanercept
  • body mass and hip disorders
  • body mass and inflammation
  • Body mass and juvenile idiopathic arthritis (JIA)
  • body mass and obesity
  • Body mass and osteoporosis
  • body mass and Personalized Medicine
  • body mass and pharmacokinetics
  • body mass and prognostic factors
  • body mass and psoriatic arthritis
  • body mass and rheumatoid arthritis (RA)
  • body mass and tumor necrosis factor (TNF)
  • BOLD
  • Bone
  • Bone and gout
  • Bone and imaging techniques
  • Bone and inflammation
  • Bone and magnetic resonance imaging (MRI)
  • Bone and osteoblasts
  • Bone and prognostic factors
  • Bone and sarcoidosis
  • Bone and uric acid
  • bone attenuation coefficient and vertebral fracture
  • bone biology
  • bone biology and dendritic cells
  • bone biology and rheumatoid arthritis (RA)
  • bone biology and WNT Signaling
  • Bone density
  • bone density and bone quality
  • bone density and Cell Migration
  • bone density and dual energy x-ray absorptiometry (DEXA)
  • bone density and fracture risk
  • bone density and fractures
  • bone density and glucocorticoids
  • Bone density and metabolic syndrome
  • Bone density and osteoarthritis
  • bone density and osteoporosis
  • Bone density and physical activity
  • bone density and psoriatic arthritis
  • bone density and radiography
  • bone density and radiology
  • Bone density and rheumatoid arthritis (RA)
  • bone density and risk
  • bone density and sarcopenia
  • Bone density and spondylarthropathy
  • bone density and steroids
  • Bone density and systemic lupus erythematosus (SLE)
  • bone density and treatment
  • Bone density and uric acid
  • bone disease
  • bone disease and genetic disorders
  • bone disease and imaging techniques
  • bone disease and osteoclastogenesis
  • bone disease and osteoporosis
  • bone disease and rheumatoid arthritis (RA)
  • bone disease and treatment
  • bone disease and x-ray
  • Bone erosion
  • bone formation and adenosine receptors
  • bone health
  • Bone marrow
  • bone marrow and interferons
  • bone marrow and macrophage activation syndrome
  • bone marrow and osteoarthritis
  • Bone marrow and osteoclasts
  • bone marrow and rheumatoid arthritis (RA)
  • Bone marrow and scleroderma
  • bone marrow and systemic lupus erythematosus (SLE)
  • bone marrow lesions
  • bone marrow lesions and diagnostic imaging
  • bone marrow lesions and inflammation
  • bone marrow lesions and osteoarthritis
  • bone marrow lesions and rheumatoid arthritis (RA)
  • bone metabolism
  • bone metabolism and bone remodeling mediators
  • Bone metabolism and rheumatoid arthritis (RA)
  • Bone metabolism and spondylarthritis
  • Bone mineral density
  • bone mineral density and frailty
  • Bone Morphogenetic Protein (BMP)
  • bone remodeling
  • bone remodeling and biopsies
  • bone remodeling and fractures
  • bone remodeling and prostaglandins
  • bone remodeling and rheumatoid arthritis (RA)
  • bone remodeling and spondylarthropathy
  • Bone Resorption
  • Bone turnover markers
  • bone turnover markers and bone density
  • bone turnover markers and inflammation
  • bone turnover markers and modified stoke ankylosing spondylitis spinal score (MSASSS)
  • Bone turnover markers and systemic lupus erythematosus (SLE)
  • Bortezomib
  • Bortezomib and SLE
  • botulinum toxin
  • botulinum toxin and pain management
  • botulinum toxin and treatment
  • Bowel
  • BR3
  • Brain
  • Brain Biopsy
  • Brain-derived neurotrophic factor
  • Brain-derived Neurotrophic Factor and Neuropsychological Assessment
  • BRD4 and systemic sclerosis
  • Breastfeeding
  • Brief Pain Inventory
  • Brodalumab
  • Bromodomain
  • bronchoalveolar lavage fluid and morbidity and mortality
  • BTK
  • BTK and rheumatoid arthritis (RA)
  • Burden of Adverse Drug Reactions
  • bursal puncture
  • business
  • business and rheumatoid arthritis (RA)
  • C protein-induced myositis
  • C Reactive Protein
  • C Reactive Protein and synovitis
  • C-reactive protein (CRP)
  • C-reactive protein (CRP) and Aging
  • C-reactive protein (CRP) and autoantibodies
  • C-reactive protein (CRP) and Disease Activity
  • C-reactive protein (CRP) and interleukins (IL)
  • C-reactive protein (CRP) and laboratory and imaging evaluation
  • C-reactive protein (CRP) and renal disease
  • C-reactive protein (CRP) and rheumatoid arthritis (RA)
  • C-reactive protein (CRP) and scleroderma
  • C1q
  • C1q and systemic lupus erythematosus (SLE)
  • C4 gene
  • C4B gene
  • C4BL gene
  • cachexia and myostatin
  • cadherin-11
  • Cadherins
  • calcinosis
  • calcinosis and dermatomyositis
  • Calcinosis and juvenile dermatomyositis
  • calcinosis and pyrophosphate
  • Calcinosis and scleroderma
  • Calcinosis and systemic sclerosis
  • Calcinosis and treatment
  • Calcitonin
  • Calcium
  • calcium and cardiovascular disease
  • Calcium and denosumab
  • Calcium and mesenchymal stem cells
  • calcium and rheumatoid arthritis (RA)
  • calcium and signal transduction
  • calcium and tendonitis/bursitis
  • Calcium and vasculitis
  • Calcium pyrophosphate dihydrate (CPPD)
  • Calcium pyrophosphate dihydrate (CPPD) and chondrocytes
  • Calcium pyrophosphate dihydrate (CPPD) and diagnosis
  • calcium pyrophosphate dihydrate (CPPD) and Electronic Health Record
  • Calcium pyrophosphate dihydrate (CPPD) and pseudogout
  • Calcium pyrophosphate dihydrate (CPPD) and rheumatoid arthritis (RA)
  • Calcium pyrophosphate dihydrate (CPPD) and synovial fluid
  • calcium pyrophosphate dihydrate (CPPD) and ultrasound
  • calcium signaling
  • Calgranulin
  • CALIPER and survival
  • calprotectin
  • calprotectin and atherosclerosis
  • calprotectin and longitudinal studies
  • CaMKIV and Treg
  • canakinumab
  • First |
  • « Previous Page
  • 5
  • 6
  • 7
  • 8
  • 9
  • [10]
  • 11
  • 12
  • 13
  • 14
  • 15
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology